Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market Perform on Tuesday, boosting sales ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

After months of investor apathy, Bristol-Myers Squibb's business is finally starting to blossom. One of his most recent ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

We’re maintaining our fair value estimate for AbbVie at $176 and slightly raising our fair value for Bristol-Myers Squibb to ... approved schizophrenia drug Cobenfy. However, both phase 2 ...

Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market Perform on Tuesday, boosting sales projections for the company’s new schizophrenia therapy Cobenfy following a ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Bristol Myers (BMY) to $61 from $57 and keeps a Market Perform ...

Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.

Cobenfy, which comes in capsule form ... chief commercialization officer for Bristol Myers Squibb, which will distribute the drug. Psychiatrists anticipate the drug could help more people to ...